Fox Hill Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fox Hill Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$279K	Hold	625	–	–	0.13%	93
2025 Q4	$283K	Sell	625 -24	-4%	-$10.3K	0.13%	90
2025 Q3	$254K	Sell	649 -34	-5%	-$14.2K	0.12%	98
2025 Q2	$304K	Buy	683 +6	+0.9%	+$2.77K	0.16%	86
2025 Q1	$328K	Sell	677 -1	-0.1%	-$466	0.19%	79
2024 Q4	$273K	Sell	678 -15	-2%	-$6.95K	0.15%	84
2024 Q3	$322K	Buy	693 +25	+4%	+$12K	0.18%	80
2024 Q2	$313K	Sell	668 -19	-3%	-$8.25K	0.19%	74
2024 Q1	$287K	Buy	687 +15	+2%	+$6.34K	0.19%	82
2023 Q4	$273K	Buy	+672	New	+$248K	0.21%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fox Hill Wealth Management's VRTX Position: Q1 2026 in Review

Fox Hill Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 625 shares worth $279K. The position accounts for 0.13% of the portfolio, ranked #93.

Fox Hill Wealth Management first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $328K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fox Hill Wealth Management held 625 shares of Vertex Pharmaceuticals worth $279K as of Q1 2026.
Fox Hill Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.13% of Fox Hill Wealth Management's portfolio in Q1 2026, its #93 holding.
Fox Hill Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Fox Hill Wealth Management's Vertex Pharmaceuticals position peaked at $328K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fox Hill Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.